The Tisch Cancer Institute at Mount Sinai | Strategic Alliance Partners

Nicholas Rohs, MD, discusses the progress made with chemoimmunotherapy combinations in frontline non–small cell lung cancer, future research directions, and emerging approaches that seek to propel progress in this disease.

Edward Wolin, MD, discusses the current treatment landscape of neuroendocrine tumors.

Deborah B. Doroshow, MD, PhD, discusses the impact of the coronavirus disease 2019 pandemic on cancer care.

Deirdre J. Cohen, MD, MS, an expert in pancreatic and other gastrointestinal cancers as well as an accomplished clinical trial leader, has joined Mount Sinai Health System as Director of the Gastrointestinal Oncology Program and Medical Director of the Cancer Clinical Trials Office at The Tisch Cancer Institute.

John O. Mascarenhas, MD, discusses the need to develop curative therapies in myelofibrosis.

Joshua Richter, MD, discusses the importance of optimizing these novel therapies to make way for precision medicine in multiple myeloma.

John O. Mascarenhas, MD, discusses the potential role of pacritinib in myeloproliferative neoplasms.

Shambavi Richard, MD, discusses the benefit of adding daratumumab to lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma.

Ajai Chari, MD, discusses the approval of belantamab mafodotin-blmf in ​relapsed/refractory multiple myeloma. 

Joshua Richter, MD, discusses the importance of optimizing available therapies in multiple myeloma. 

Shambavi Richard, MD, highlights the rapidly evolving armamentarium ​in multiple myeloma.

Joshua Richter, MD, discusses the utility of isatuximab in relapsed/refractory multiple myeloma.

Ajai Chari, MD, discusses the recent approval of belantamab mafodotin in relapsed/refractory multiple myeloma and other emerging agents under exploration in the space.

Adilia Hormigo, MD, PhD, discusses the current treatment landscape of glioblastoma.

Ajai Chari, MD, discusses next steps with belantamab mafodotin-blmf and combination studies in multiple myeloma.

Shambavi Richard, MD, discusses treatment according to transplant eligibility in multiple myeloma. 

Ronald Hoffman, MD, discusses the current polycythemia vera treatment paradigm.

John P. Sfakianos, MD, discusses the utility of adjuvant therapy in bladder cancer management.

Joshua Brody, MD, discusses addressing required resistance to immunotherapy in non-Hodgkin lymphoma.

John O. Mascarenhas, MD, discusses patient characteristics and outcomes following ruxolitinib discontinuation in myelofibrosis and research efforts being made to address a large unmet need in the space.

Che-Kai Tsao, MD, shares strategies to improve outcomes in renal cell carcinoma.

Che-Kai Tsao, MD, shares strategies to improve outcomes in renal cell carcinoma.

John P. Sfakianos, MD, discusses the importance of restaging transurethral resection of bladder tumors.

John P. Sfakianos, MD, discusses the importance of restaging transurethral resection of bladder tumors.

William K. Oh, MD, discusses challenges with developing novel targeted agents in prostate cancer.

William K. Oh, MD, discusses adapting the phase 2 PRINT trial model to other settings in prostate cancer

Michael L. Grossbard, MD, discusses the activity of venetoclax in follicular lymphoma.

William K. Oh, MD, discusses the importance of identifying DNA damage repair mutations in prostate cancer.

Joshua Brody, MD, discusses the role of immunotherapy in indolent lymphomas.

Michael L. Grossbard, MD, discusses the phase III DYNAMO study examining the use of duvelisib in the treatment of patients with indolent non-Hodgkin lymphoma.